by Walter Jessen on Monday, May 14, 2012
Scientists at the Children’s Hospital Oakland Research Institute (CHORI) Nutrition & Metabolism Center recently announced that they have developed a low-calorie, high-fiber, fruit-based vitamin and mineral nutrition bar called the CHORI-bar, which improves biomarkers linked to risk of cardiovascular disease, cognitive decline, and associated decline in antioxidant defenses.
(No Ratings Yet)
Print story
Like this article? Highlight HEALTH delivers weekly articles on the science of health. Join the community by subscribing (more).
by Diana Gitig on Monday, February 13, 2012
Scientists have long debated whether Alzheimer’s disease starts in separate regions of the brain independently and at different times, or if it begins in one region and then spreads. Data from researchers at Columbia University Medical Center supports the latter model, showing that abnormal tau protein — a key feature observed in the brains of patients with Alzheimer’s disease — propagates along anatomically connected networks, between connected and vulnerable neurons. The study was published earlier this month in the online journal PLoS ONE [1].
Image credit: Neurons network in human brain via Shutterstock (No Ratings Yet) Print story
Like this article? Highlight HEALTH delivers weekly articles on the science of health. Join the community by subscribing (more).
by Walter Jessen on Monday, January 30, 2012
Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.
Selventa, a biomarker discovery company that enables personalized healthcare through the stratification of patients based on disease-driving mechanisms, recently announced a US patent that relates methods and techniques that facilitate discovery of biomarkers, thus aiding in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.
Increasing emphasis is being placed on biomarker discovery as the key to advancing personalized medicine.
Critical Diagnostics is a U.S.-based biomarker company focused on optimizing patient care in cardiovascular diseases, such as heart failure.
The success of personalized cancer therapeutics relies on the development of companion diagnostic assays that can identify the most appropriate cancer patient, tumor type and disease state. To address this need, SciClips, a Wisconsin-based open innovation platform company that enables scientists and researchers to collaborate and share research and ideas, recently launched a cancer (oncology) biomarker database.
The Bill & Melinda Gates Foundation is currently seeking letters of inquiry for the grant program Biomarkers of Gastrointestinal (Gut) Function and Health.
(No Ratings Yet) Print story
Like this article? Highlight HEALTH delivers weekly articles on the science of health. Join the community by subscribing (more).
by Walter Jessen on Monday, October 10, 2011
Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.
A satellite symposium, Recent Advances in Biomarker Discovery for Parkinson’s Disease, is being sponsored by Covance on November 13th, 2011 at the Society for Neuroscience Annual Meeting in Washington, D.C.
The New York Academy of Sciences (NYAS) will be holding an afternoon event in January 2012 that focuses on biomarkers and brain imaging of presymptomatic Alzheimer’s disease.
Earlier this month, the National Institutes of Health announced that the National Institute of Dental and Craniofacial Research (NIDCR) Institute will support mission-relevant investigator-initiated Phase I, II, III or IV clinical trial cooperative agreement applications or biomarker evaluation studies that require prospective collection of clinical outcomes and clinical specimens.
The National Institutes of Health announced Thursday that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will support studies that propose adapting adult biomarkers to children.
CLC bio is participating in a $4 million Danish collaboration focused on the identification and validation of biomarkers of prostate cancer risk and aggressiveness.
(No Ratings Yet) Print story
Like this article? Highlight HEALTH delivers weekly articles on the science of health. Join the community by subscribing (more).
by Walter Jessen on Tuesday, August 23, 2011
Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.
Diagnostics used to select patients for treatment with a particular therapeutic or determine what and/or how treatment will be administered have been termed companion diagnostics. Companion diagnostics hold great promise for personalized medicine. A companion diagnostic is a biomarker(s) used in a specific context that provides biological and/or clinical information that enables better decision making about the development and use of a potential therapeutic. Given the significance of companion diagnostics, I’m proud to announce Biomarker Commons’ first media partnership with the 4th World Companion Diagnostics Summit.
Personalized medicine is a term used in science and medicine that holds significant promise of administering medicines specifically tailored to an individual’s genome or metabolism. However, an editorial published yesterday in the Canadian Medical Association Journal (CMAJ) suggests that the term creates an image for the public that is completely opposite of science and technology and sets up unrealistic expectations.
Regulators in the U.S. and Europe have each posted requests for public comment on issues affecting the development of medicines by drug companies.
The U.S. Food and Drug Administration (FDA) has issued new guidelines on biomarkers related to drug or biotechnology product development. The guidance was developed within the Efficacy Working Group of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
In response to facial expression of emotional, a similar pattern of brain activity is observed in both people with autism and their unaffected siblings. Researchers from the University of Cambridge recently used functional magnetic resonance imaging (fMRI), a specialized MRI scan used to measure the change in blood flow related to neural activity in the brain, to show that reduced activity in areas of the brain associated with empathy and face processing is a candidate biomarker for familial risk of autism. The findings were published online recently in the journal Translational Psychiatry.
(No Ratings Yet) Print story
Like this article? Highlight HEALTH delivers weekly articles on the science of health. Join the community by subscribing (more).
(3.00 out of 5)
